This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Coronary Disease - PCI

December 5, 2016
In the largest randomized trial on PCI versus CABG in patients with left main disease (n=1905) and with an inclusion criteria of a SYNTAX score >33, PCI with everolimus-eluting stents was non-inferior to CABG for the composite endpoint of death, stroke, and myocardial infarction at a trial of 3-year follow-up (15.4% versus 14.7%, respectively).
November 23, 2016
In this  retrospective study of propensity-matched patients undergoing CABG, the authors queried whether prior PCI adversely affected outcomes.  9% of over 4500 pts undergoing first time CABG had prior PCI.  There was no difference between the groups with regard to hospital mortality or 10-year survival. 
November 7, 2016
This is a prospective, randomised, open-label, non-inferiority trial comparing CABG versus PCI in patients with unprotected left main stenosis. The study was carried out at 36 hospitals in Latvia, Estonia, Lithuania, Germany, Norway, Sweden, Finland, the UK, and Denmark.
October 12, 2016
In the FREEDOM trial, 1900 diabetic patients were randomized between coronary bypass surgery and percutaneous coronary intervention (PCI). Of these, 451 patients had chronic kidney disease (CKD) with a GFR 30-60 mL/min/1.73m2, and the remaining patients were categorized as having no CKD.
July 6, 2016
What effect has the SYNTAX trial had on practice in Europe? Philippe Kolh reviews the trial and its guidelines.
June 11, 2016
The authors compare single-institution retrospective data on outcomes of coronary bypass grafting or PCI for isolated CAD in over 12,000 pts.  Overall survival was better for PCI patients (46% vs 34% at 15 yrs).  However, survival for patients undergoing CABG with multiple arterial grafts was superior to most other interventions at 15 years and was s
April 3, 2016
In a propensity-matched analysis, Rosenblum and colleagues found that hybrid revascularization as compared with coronary artery bypass grafting with either single or bilateral internal mammary artery grafts was superior in terms of secondary short-term outcomes (e.g.
March 29, 2016
Joseph Sabik of the Cleveland Clinic, Cleveland, Ohio, considers whether the SYNTAX trial changed cardiology and cardiothoracic surgery practice in the United States.
March 23, 2016
Guidelines recommend that ICDs should not be implanted until after 90 days following revascularization in patients with an EF<35% and an MI.  Studies have shown that no clinical benefit or detriment was derived by implantation prior to 90 days.
March 11, 2016
The authors provide an excellent overview of the rationale for screening all patients with a new diagnosis of cardiomyopathy for coronary artery disease.  This rationale includes the following: